Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
NeurAxis, Inc. commercializes neuromodulation therapies for chronic and debilitating conditions in children and adults. The company’s proprietary IB-Stim product uses Percutaneous Electrical Nerve Field Stimulation, or PENFS, and is FDA cleared for functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and FD-related nausea symptoms in patients 8 years and older.
Recurring NeurAxis news includes FDA clearance updates, reimbursement and coding developments, medical policy coverage decisions, commercial access through payer and government channels, and adoption of PENFS in clinical practice. Company updates also cover quarterly financial results, business update calls, preferred stock dividends, equity and balance-sheet activity, and changes involving licensed neuromodulation assets.
NeurAxis (NYSE American: NRXS) reported record second quarter 2026 results, with revenues rising 116% year over year to $1.93 million, driven by increased payer coverage following the January 1, 2026 Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS).
Unit deliveries grew 60% year over year and gross margin improved to 85.9% from 83.6%, reflecting a shift from discounted assistance programs to fully reimbursed procedures. Cash stood at $8.3 million on June 30, 2026, with operating cash use reduced to $1.0 million versus $1.5 million a year earlier.
The company highlighted several milestones: VA Federal Supply Schedule contract award, first-ever FDA clearance for IB-Stim in functional dyspepsia abdominal pain (ages 8+), and pediatric guidelines recommending its PENFS technology for functional abdominal pain in IBS.
NeurAxis (NYSE American: NRXS) announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, adding access for over 500,000 covered lives and expanding IB-Stim availability for beneficiaries in the Mid-Atlantic region.
According to NeurAxis, this incremental coverage supports its strategy to achieve comprehensive nationwide written policy coverage for IB-Stim. The company highlights implementation of a Category I CPT code and inclusion of its PENFS technology in leading clinical guidelines as reinforcing IB-Stim’s clinical and economic value among payers. IB-Stim is FDA-cleared for functional abdominal pain associated with IBS and functional dyspepsia, including FD-related nausea, in patients 8 years and older, and is positioned as the only FDA-cleared therapy specifically designed for pediatric abdominal pain-related DGBIs.
NeurAxis (NYSE American: NRXS) will release summarized financial results for its second quarter ended June 30, 2026, before market open on Tuesday, August 11, 2026. The company will host a conference call the same day at 9:00 a.m. ET to review the results, with live phone and webcast access plus a replay option.
NeurAxis (NYSE American: NRXS) reported record Q1 2026 revenue of $1.6 million, up 80% year over year, with unit deliveries up 35%. Gross margin rose to 86.4%, and operating loss declined 24%, supported by expanded insurance coverage from the new Category I CPT® code.
Cash was $7.1 million on March 31, 2026, plus $2.1 million raised afterward. NeurAxis highlighted new FDA clearances for IB-Stim, VA Federal Supply Schedule access, and pediatric guideline recommendations, broadening its addressable market.
NeurAxis (NYSE American: NRXS) will report summarized financial results for the first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026 before market open. The company also scheduled a conference call the same day at 9:00 AM ET to review results, with webcast and replay details provided.
Dial-in numbers, webcast link, and replay access code are available for investors and analysts to listen live or access the replay.
NeurAxis (NYSE: NRXS) announced four additional medical policies for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 1.25 million covered lives and extending access in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.
The company cited Category I CPT code recognition, inclusion in clinical guidelines, FDA clearance of IB-Stim for specified DGBI indications in patients age 8+, and disclosed an auditor’s explanatory paragraph noting substantial doubt about going concern for fiscal year 2025.
NeurAxis (NYSE American: NRXS) declared a stock dividend on its Series B preferred stock on April 10, 2026. Holders of record as of April 21, 2026 will receive common stock based on accrued unpaid dividends divided by $2.38. The dividend is payable April 28, 2026.
Approximately 510,605 shares of common stock are expected to be issued; no fractional shares will be issued and fractional entitlements will be paid in cash calculated at $2.38 per fractional share.
NeurAxis (NYSE: NRXS) reported strong revenue growth and strategic commercial wins for 4Q25 and FY2025. Revenue grew 27% in 4Q25 to $968k and 33% for FY2025 to $3.6M. Operating loss widened to $1.7M in 4Q25 and $7.8M for FY2025; cash was $5.0M at year-end.
Key commercial milestones include a Category I CPT code effective Jan 1, 2026, a VA Federal Supply Schedule contract, expanded FDA clearance for IB-Stim for abdominal pain in patients 8+ years, and post-year At-The-Market proceeds of $2.6M.
NeurAxis (NYSE American: NRXS) will report summarized fourth quarter and full year 2025 results for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open.
The company will host a conference call and live webcast on March 19, 2026 at 9:00am ET; webcast and replay will be available in the Investor Relations section of the company's website. Participants can submit questions via the webcast portal or by emailing NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS) announced that an AMA Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect as of Jan. 8, 2026. The code establishes a permanent, nationally recognized coding and billing pathway for NeurAxis’ IB-Stim therapy, signaling broad clinical acceptance and meeting AMA criteria for widespread utilization and clinical efficacy. Management said the code should improve payer alignment, reimbursement predictability, and scalability across health systems, potentially accelerating patient access and supporting long-term commercial growth. Management will present at the Lytham Partners Healthcare Investor Summit on Jan. 15, 2026.